The private and public sectors are coming together to boost investment in South West Western Australia
Regional Development Australia – South West Chairman Duncan Anderson announced that Go Geo Ltd and RDA SW will work together to produce a South West Regional Investment Framework.
Go Geo, alongside BlueMount Capital, are establishing the South West Managed Investment Fund. BlueMount is a member of the International Association of Investment Bankers, and the new fund will be a cornerstone investor in qualified companies and projects that have a positive impact on the region’s economy.
Mr Anderson said: “We have been grappling with how to bring the South West Blueprint to life. The federal government and the state government have already done the heavy lifting, we now need to embrace and support private funds”
In partnership with Go Geo, RDA South West are developing a regional investment framework. That framework is designed to bridge the gap between government planning priorities and the world of private equity.
The framework is determined in alignment with the Blueprint. Priority opportunities will be determined by an advisory group of initiators providing expertise in industry and sub sectors as required.
General Manager of Go Geo, Emma Nesbitt said: “The need for this framework came out of a growing interest, for businesses and industry to invest in both new and existing projects. This provides the vehicle.”
Mr Anderson said: “It’s a marvellous opportunity for our region. There are not many regions nationally that successfully bridge the gap between private and public planning.”
By using a framework that operates at the public and private level, the region can take best advantage of its opportunities and nurture some excitement.
Ms Nesbitt said: “In order to entertain the idea of external equity entering our region, and to facilitate such discussions, we need to ensure due diligence and sound governance. Through this process and the framework, we enable the region to retain control over planning measures whilst using progressive and modern influences to entice excitement, development and funding, which in turn broadens external markets and creates new jobs.”
The next step is the establishment of an independent body to oversee the investment fund, which will come to fruition over the coming few weeks.
Media contact: Emma Nesbitt. e: firstname.lastname@example.org m: 0406 056 926.
Media contact: Charles Jenkinson e: email@example.com m: 0434 641 111
Bangladesh Infrastructure Finance Fund Limited and BlueMount Capital execute Memorandum of Understanding (MOU)
- Bangladesh Infrastructure Finance Fund Limited and BlueMount Capital execute Memorandum of Understanding (MOU) to cooperate
- The MOU sets out the basis for collaboration to secure international finance and investments for selected infrastructure and green technology projects
- The Parties will target several major projects for international financing
Bangladesh Infrastructure Finance Fund Limited (BIFFL), one of the major government-owned non-bank financial institutions focused largely on infrastructure projects and BlueMount Capital, an Australian-headquartered corporate finance house signed an MOU to collaborate on international financing of infrastructure and green projects in Bangladesh.
Bangladesh’s GDP has grown at a rate of 7% per annum for the past 10 years and the country has enormous infrastructure financing requirement to meet its goal of becoming a middle-income country by 2021 and achieving Sustainable Development Goals (SDG) by 2030.
BIFFL has already financed 40 projects in Bangladesh and have a robust project pipeline at different stages of development.
Traditionally, Bangladesh has utilised soft-loan funds from the Asian Development Bank, World Bank and similar international finance institutions.
Under the MOU, BlueMount Capital will work with BIFFL on corporate and commercial investment and financing channels.
The Parties will cooperate to secure support from the Bangladesh Government for guarantees and appropriate incentives, in applicable cases, to attract international investment.
“We are pleased with this initiative to broaden our inbound investment channels with an international corporate finance house such as BlueMount Capital,” said the Executive Director and CEO of BIFFL Mr S.M. Formanul Islam.
“Bangladesh has several attractive infrastructure and energy projects ranging in scale and stages of development,
“We have more than US$ 2 billion of investment and financing opportunities for infrastructure and energy projects” said Mr Islam.
BlueMount Capital Chairman Dr Saliba Sassine said the group is looking forward to working closely with BIFFL and to promoting investment opportunities to international investment houses focused on emerging markets or energy and infrastructure opportunities.
“Bangladesh location makes it a strategic bridge between South Asia and South East Asia,” said Dr Sassine.
“Combined this with strong growth over the past decade, a liberal and multi-party system of government and a good mix of skills and education among its workforce, Bangladesh is well poised to become a strong Tiger Economy.”
BIFFL and BlueMount aim to action their efforts in early 2019 with a selection of opportunities.
Bangladesh Infrastructure Finance Fund Limited
BlueMount Capital (WA) Pty Ltd
Bangladesh Infrastructure Finance Fund Limited is one of the major government-owned non-bank financial institutions focused largely on infrastructure projects and has finance 40 major infrastructure and energy projects in Bangladesh
About BlueMount Capital
BlueMount Capital is an Australia national investment bank and corporate finance group assisting and advising corporate clients on listing on the ASX, M&A, private placements, cross border transactions and the raising of capital from the equity and debt markets.
BlueMount Capital is pleased to advise that we have been appointed Corporate Advisor by Qponics Limited.
Qponics Limited is a Brisbane based company focused on the sustainable production of EPA Omega-3 oils and other high-value products from Australian strains of algae.
The Company is planning to upgrade the existing pilot algae farm, to purchase a property for its commercial algae farm and submitting the DA and preparing to list on a suitable Australian stock exchange via an IPO in 2019.
The upgraded pilot algae farm in Brisbane and Qponics’ largescale algae farm to be built on the proposed 167.5 ha site at South Ballina will sustainably produce algae, from which omega-3 oil and high-protein biomass as a by-product will be extracted, integrating state-of-the-art technologies to maximise automation and minimise operational costs.
Our assignment will comprise being the corporate advisor, and raising funds now for a pre-IPO raising of $7M immediately followed by an IPO in 2019. For more information please click here or contact us.
Dr Mark Rainbird
BlueMount Capital is pleased to report we are assisting an exciting Melbourne based antibody drug development Company to raise funds and with strategic advice.
Imunexus Ltd is a public unlisted Australian company that develops bispecific antibody based drugs.
The Company promises exceptional growth potential in the disciplines of clinical oncology and immunology. Innovative cancer therapeutics are driving value in the pharmaceutical industry, with many newly marketed engineered antibodies taking the lead in their fields.
Using its proprietary library of over 1010 (ten billion) engineered antibodies; Imunexus has identified several drug candidates that the Company aims to take through the drug development process.
Imunexus’ competitive advantage is that unlike most antibody therapeutic companies, Imunexus’ technology can be taken from concept to the identification of drug candidates within less than six months. This advantage is key to Imunexus’ potential.
Progressing, the Company has identified several drug candidates that possess drug-like characteristics. Of these, IMX101 is the closest to entering human clinical trials.
Targeting cancer, IMX101 was characterised and the Company appointed BlueMount to source the funds to complete formal Preclinical Studies that would enable IMX101 to enter Phase I human clinical trials. In parallel, Imunexus shall also advance its other drug candidates and identify new candidates.
With such a deep pool of investigational drugs, Imunexus is positioned to extract value via both 1) the development of drugs in human clinical trials and 2) license the development of non-core drug candidates to industry parties. BlueMount’s assignment comprises being the corporate advisor and are raising funds now of up to $5 million.
BlueMount Capital has been appointed as Corporate Advisor to PROJECT ENERGISE. The client carbonTRACK has developed advanced and innovative software and hardware which allows users to monitor, manage and optimize their energy usage, maximising savings and even allowing users to trade and arbitrage energy.
With its head office located in Melbourne, carbonTRACK commenced operations in 2015. Since then this award winning technology has been deployed in Australia New Zealand and Africa. Funds are now being raised to expand current operations and to support entry and growth in the U.S.A.
BlueMount Capital will lead the raising of $10m. An Investment Deck and Information Memorandum are now available and further details can be accessed on this website.
BlueMount Capital Appointed as Corporate Advisor and Joint Lead Manager for Integrative Health Care Limited (IHC) ASX IPO
BlueMount Capital is pleased to advise that we have been appointed Corporate Advisor and Joint Lead Manager (with Patersons Securities) for the upcoming IPO of Integrative Health Care Limited (IHC).
BlueMount Capital Sydney has partnered with a leading private non-bank lender with a capital pool of $1.3B for commercial property developers that specialises in loans from $1M to $200M.
In 2017 the lender settled $1.8B in loans and looks set to exceed $2B in the financial year to June 2018. Developments can be both residential or commercial in any state with a preference for capital cities or larger regional centres.
Loans are available for property developers for the following types of projects;
- Bridging finance
- Construction finance
- Commercial Property purchases and refinance
- Residential Property where the funds are used for commercial purposes
- Land Banking for developers
- Development Sites
Rates start from 6.5% plus line & establishment fees.
Initial Documentation Required
- Overview of the project with key metrics summarised
- Valuation if available. An old report will suffice. If a valuation is not available, please provide the address and estimated value.
- Copy of the contract of sale (if acquisition).
- Details (lender and outstanding balance) of any mortgages currently on the property.
- Feasibility study for the project – for a construction loan only
- Level of presales achieved to date. – for a construction loan only
For more information or to make an application contact Ross McDowall in the Sydney office.
“In conjunction with BlueMount Capital’s Melbourne office, I am delighted to announce we have secured more than AUD 39 million in debt funding for a leading Melbourne based manufacturing group.
The funds will be used to finalise the purchase of a new factory as well as providing flexible growth oriented banking facilities. The funding includes a range of facilities such as business loans; equipment, trade and invoice finance as well as an overdraft and credit card facilities.
BlueMount Capital worked closely with the new funder and the client to secure the facilities which include more flexible covenants and guarantee arrangements while providing competitive interest rates on all products offered.”
Dr Mark Rainbird
BlueMount Capital was featured in the recent Australia & New Zealand Business Report 2017 in the South China Morning Post.
You can read the full text of the story on the South China Morning Post’s website or download the Australia & New Zealand Business Report 2017
BlueMount Capital is pleased to announce that the Initial Public Offer for Haixi Pharmaceutical International Holdings Limited has opened for investors.
Key IPO Details
- Substantial increasing profits and assets with high margins
- First Chinese pharmaceutical company to be listed on the ASX
- Long-standing brand recognition with 20 years history
- High dividend payout ratio planned at 50% of NPAT, payable twice a year
- Value investment at a P/E lower than sector average on ASX and HKEX
- Plans to expand into the Australian market and intends to acquire or invest in Australian companies in the pharmaceutical sector
- China is the worlds second largest market for pharmaceuticals
The Prospectus for the offer and a Company Presentation can be obtained via:
Open Date: 21 July 2017
Close Date: 27 October 2017
Minimum Investment A$ 2,000